FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892076116> ?p ?o ?g. }

• W2892076116 abstract "Abstract Background The aim of this study is to compare the outcome of patients with adenocarcinoma of the distal oesophagus (AEG Type I) treated with perioperative chemotherapy or neoadjuvant chemoradiation. Methods A retrospective analysis of eligible patients from four Austrian centers was conducted. All patients with AEG type I treated between January 2007 and October 2017 with chemotherapy (EOX-protocol) or chemoradiation (CROSS-protocol, or 5-FU/Cisplatin), followed by oesophagectomy were included in the study. Primary outcomes overall survival, and disease free survival as well as secondary outcomes, achievement of pathological complete response pCR (ypT0N0M0) or downstaging of T- or N-stage were analyzed. Primary outcomes were calculated by the Kaplan-Meier-method. Results Data of 117 patients were analyzed, 59 received chemoradiation (50/59 CROSS and 9/59 5-FU/Cisplatin) and 58 patients received perioperative chemotherapy (EOX). Complete data at time of submission were available in 40 patients in the chemoradiation group and in 37 patients in the chemotherapy group. The median follow-up time in the chemoradiation group was 13,0 months (CI 95%: 11,0–15,0) and in the chemotherapy group 45,0 months (CI 95%: 28,8–61,3). Overall survival rate in the EOX group after ½, 1, 3 and 5 years was 92%, 83%, 63% and 34%. So far long term data are not available after chemoradiation, after ½ year overall survival was 84% and after one year 60%. Disease free survival rate in the EOX group after ½, 1, 3 and 5 years was 91%, 81%, 54% and 32%, in the chemoradiation group after ½ and one year 80% and 50%. A significant difference was found in the pathological complete response (pCR) rate, it was achieved in 19% of patients after chemoradiation and in 3% after chemotherapy (P = 0000). Conclusion Concerning major response of the primary tumor there are clear advantages for chemoradiation. In regards to systemic tumor control there seems a tendency in favor for chemotherapy. Disclosure All authors have declared no conflicts of interest." @default.
• W2892076116 created "2018-09-27" @default.
• W2892076116 creator A5000184140 @default.
• W2892076116 creator A5016344736 @default.
• W2892076116 creator A5017051808 @default.
• W2892076116 creator A5027871513 @default.
• W2892076116 creator A5035611738 @default.
• W2892076116 creator A5045741656 @default.
• W2892076116 creator A5045898693 @default.
• W2892076116 creator A5070617335 @default.
• W2892076116 creator A5081145254 @default.
• W2892076116 creator A5082430890 @default.
• W2892076116 creator A5085701315 @default.
• W2892076116 date "2018-09-01" @default.
• W2892076116 modified "2023-09-22" @default.
• W2892076116 title "PS02.115: PERIOPERATIVE CHEMOTHERAPY VERSUS NEOADJUVANT CHEMORADIATION FOR PATIENTS WITH ADENOCARCINOMA OF THE DISTAL OESOPHAGUS IN AUSTRIA" @default.
• W2892076116 doi "https://doi.org/10.1093/dote/doy089.ps02.115" @default.
• W2892076116 hasPublicationYear "2018" @default.
• W2892076116 type Work @default.
• W2892076116 sameAs 2892076116 @default.
• W2892076116 citedByCount "0" @default.
• W2892076116 crossrefType "journal-article" @default.
• W2892076116 hasAuthorship W2892076116A5000184140 @default.
• W2892076116 hasAuthorship W2892076116A5016344736 @default.
• W2892076116 hasAuthorship W2892076116A5017051808 @default.
• W2892076116 hasAuthorship W2892076116A5027871513 @default.
• W2892076116 hasAuthorship W2892076116A5035611738 @default.
• W2892076116 hasAuthorship W2892076116A5045741656 @default.
• W2892076116 hasAuthorship W2892076116A5045898693 @default.
• W2892076116 hasAuthorship W2892076116A5070617335 @default.
• W2892076116 hasAuthorship W2892076116A5081145254 @default.
• W2892076116 hasAuthorship W2892076116A5082430890 @default.
• W2892076116 hasAuthorship W2892076116A5085701315 @default.
• W2892076116 hasConcept C121608353 @default.
• W2892076116 hasConcept C126322002 @default.
• W2892076116 hasConcept C141071460 @default.
• W2892076116 hasConcept C143998085 @default.
• W2892076116 hasConcept C2776694085 @default.
• W2892076116 hasConcept C2778292576 @default.
• W2892076116 hasConcept C2781182431 @default.
• W2892076116 hasConcept C31174226 @default.
• W2892076116 hasConcept C530470458 @default.
• W2892076116 hasConcept C61434518 @default.
• W2892076116 hasConcept C71924100 @default.
• W2892076116 hasConceptScore W2892076116C121608353 @default.
• W2892076116 hasConceptScore W2892076116C126322002 @default.
• W2892076116 hasConceptScore W2892076116C141071460 @default.
• W2892076116 hasConceptScore W2892076116C143998085 @default.
• W2892076116 hasConceptScore W2892076116C2776694085 @default.
• W2892076116 hasConceptScore W2892076116C2778292576 @default.
• W2892076116 hasConceptScore W2892076116C2781182431 @default.
• W2892076116 hasConceptScore W2892076116C31174226 @default.
• W2892076116 hasConceptScore W2892076116C530470458 @default.
• W2892076116 hasConceptScore W2892076116C61434518 @default.
• W2892076116 hasConceptScore W2892076116C71924100 @default.
• W2892076116 hasLocation W28920761161 @default.
• W2892076116 hasOpenAccess W2892076116 @default.
• W2892076116 hasPrimaryLocation W28920761161 @default.
• W2892076116 isParatext "false" @default.
• W2892076116 isRetracted "false" @default.
• W2892076116 magId "2892076116" @default.
• W2892076116 workType "article" @default.